BioLife Solutions Inc (NASDAQ:BLFS) VP Sells $50,275.00 in Stock

BioLife Solutions Inc (NASDAQ:BLFS) VP James Mathers sold 2,500 shares of the stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $20.11, for a total transaction of $50,275.00. Following the completion of the transaction, the vice president now owns 19,884 shares in the company, valued at approximately $399,867.24. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

James Mathers also recently made the following trade(s):

  • On Tuesday, September 3rd, James Mathers sold 2,500 shares of BioLife Solutions stock. The stock was sold at an average price of $20.07, for a total transaction of $50,175.00.
  • On Tuesday, August 20th, James Mathers sold 2,500 shares of BioLife Solutions stock. The stock was sold at an average price of $20.06, for a total transaction of $50,150.00.
  • On Thursday, August 22nd, James Mathers sold 7,500 shares of BioLife Solutions stock. The stock was sold at an average price of $20.45, for a total transaction of $153,375.00.
  • On Tuesday, August 6th, James Mathers sold 2,500 shares of BioLife Solutions stock. The stock was sold at an average price of $17.87, for a total transaction of $44,675.00.
  • On Thursday, August 8th, James Mathers sold 2,500 shares of BioLife Solutions stock. The stock was sold at an average price of $18.21, for a total transaction of $45,525.00.
  • On Tuesday, July 23rd, James Mathers sold 2,500 shares of BioLife Solutions stock. The stock was sold at an average price of $18.38, for a total transaction of $45,950.00.
  • On Thursday, July 25th, James Mathers sold 2,500 shares of BioLife Solutions stock. The stock was sold at an average price of $19.71, for a total transaction of $49,275.00.
  • On Thursday, July 11th, James Mathers sold 2,500 shares of BioLife Solutions stock. The stock was sold at an average price of $17.15, for a total transaction of $42,875.00.
  • On Tuesday, July 9th, James Mathers sold 2,500 shares of BioLife Solutions stock. The stock was sold at an average price of $17.94, for a total transaction of $44,850.00.

BioLife Solutions stock traded down $0.52 during mid-day trading on Friday, hitting $19.51. The company had a trading volume of 192,150 shares, compared to its average volume of 166,731. The company has a current ratio of 9.42, a quick ratio of 7.71 and a debt-to-equity ratio of 0.02. BioLife Solutions Inc has a 12-month low of $9.15 and a 12-month high of $22.44. The company’s fifty day moving average is $19.05 and its 200-day moving average is $17.89. The company has a market capitalization of $380.63 million, a price-to-earnings ratio of 139.36 and a beta of 1.43.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings data on Thursday, August 8th. The medical equipment provider reported $0.04 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.02. BioLife Solutions had a return on equity of 8.65% and a net margin of 14.60%. The business had revenue of $6.70 million for the quarter, compared to analyst estimates of $6.59 million. As a group, sell-side analysts expect that BioLife Solutions Inc will post 0.08 EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the business. River & Mercantile Asset Management LLP purchased a new position in BioLife Solutions during the 2nd quarter valued at about $3,807,000. Price T Rowe Associates Inc. MD boosted its holdings in BioLife Solutions by 32.3% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 29,626 shares of the medical equipment provider’s stock valued at $502,000 after acquiring an additional 7,226 shares during the period. Citadel Advisors LLC purchased a new position in BioLife Solutions during the 2nd quarter valued at about $709,000. Marshall Wace LLP boosted its holdings in BioLife Solutions by 39.4% during the 2nd quarter. Marshall Wace LLP now owns 42,200 shares of the medical equipment provider’s stock valued at $715,000 after acquiring an additional 11,922 shares during the period. Finally, Morgan Stanley boosted its holdings in BioLife Solutions by 17.5% during the 2nd quarter. Morgan Stanley now owns 11,506 shares of the medical equipment provider’s stock valued at $195,000 after acquiring an additional 1,713 shares during the period. Institutional investors and hedge funds own 47.86% of the company’s stock.

Several brokerages recently weighed in on BLFS. BidaskClub upgraded shares of BioLife Solutions from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 22nd. Maxim Group set a $24.00 price objective on BioLife Solutions and gave the stock a “buy” rating in a research report on Friday, August 9th. HC Wainwright initiated coverage on BioLife Solutions in a research report on Monday, July 22nd. They issued a “buy” rating and a $23.00 price objective on the stock. Northland Securities upped their price objective on BioLife Solutions from $18.00 to $22.00 and gave the stock an “outperform” rating in a research report on Wednesday. Finally, ValuEngine lowered BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Saturday, August 10th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $19.33.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Further Reading: The Discount Rate – What You Need to Know

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.